Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologus cytotoxic T cell therapy - Marker Cell Therapy

Drug Profile

Autologus cytotoxic T cell therapy - Marker Cell Therapy

Alternative Names: MultiTAA T cells Stage; MultiTAA T-cell therapy; MultiTAA-specific T cells; TAA-specific CTLs

Latest Information Update: 28 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baylor College of Medicine; Marker Therapeutics
  • Developer Baylor College of Medicine; Marker Cell Therapy
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Breast cancer
  • Phase I/II Lymphoma; Multiple myeloma; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Sarcoma
  • No development reported Myelodysplastic syndromes

Most Recent Events

  • 28 Dec 2019 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(In children, In the elderly, Second-line therapy or greater, In adults) in USA (IV, Injection)
  • 12 Nov 2019 Marker Therapeutics plans a phase II trial for Acute myeloid leukaemia (Adjuvant therapy, Second-line therapy or greater) in 2020
  • 02 Oct 2019 The US FDA accepts IND application for Cytotoxic T cell therapy for Acute myeloid leukaemia (Adjuvant therapy, Second-line therapy or greater) for review before October 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top